These results highlight the potent antiproliferative and pro-apoptotic effects of bardoxolone methyl in ovarian cancer cells, primarily through suppression of the AKT/NF-κB/mTOR signaling pathway, supporting its potential as a promising therapeutic candidate for ovarian cancer [103]. Here, NFKB1 is linked to ovarian cancer.